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The newly characterized cytokine IL-38 (IL-1F10) belongs to the IL-1 family of cytokines. Previous work
has demonstrated that IL-38 inhibited Candida albicans-induced IL-17 production from peripheral blood
mononuclear cells. However, it is still unclear whether IL-38 is an inﬂammatory or an anti-inﬂammatory
cytokine. We generated anti-human IL-38 monoclonal antibodies in order to perform im-
munohistochemical staining and an enzyme-linked immunosorbent assay. While human recombinant
IL-38 protein was not cleaved by recombinant caspase-1, chymase, or PR3 in vitro, overexpression of IL-
38 cDNA produced a soluble form of IL-38 protein. Furthermore, immunohistochemical analysis showed
that synovial tissues obtained from RA patients strongly expressed IL-38 protein. To investigate the
biological role of IL-38, C57BL/6 IL-38 gene-deﬁcient (/) mice were used in an autoantibody-induced
rheumatoid arthritis (RA) mouse model. As compared with control mice, IL-38 (/) mice showed greater
disease severity, accompanied by higher IL-1β and IL-6 gene expression in the joints. Therefore, IL-38
acts as an inhibitor of the pathogenesis of autoantibody-induced arthritis in mice and may have a role in
the development or progression of RA in humans.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
IL-38 (IL-1F10) was originally cloned as an IL-1 family cytokine,
and named IL-1HY2 in 2001 [1]. A human IL-38 cDNA sequence
identiﬁed from a human fetal skin library encodes a 152-amino-
acid precursor. Human IL-38 has 4 exons, and the IL-38 gene is
located in the IL-1 family cluster on chromosome 2 next to the
genes encoding IL-1 receptor antagonist (IL-1Ra) and IL-36 re-
ceptor antagonist (IL-36Ra). IL-38 shares 37% homology with IL-
1Ra, 43% homology with IL-36Ra and has a three-dimensional
structure similar to IL-1Ra [2]. Immunohistochemical analysis
using a polyclonal antibody against an IL-38-origin synthetic
peptide (CTLPNRGLDRTKVP) has shown that the IL-38 protein is
expressed in the basal epithelia of human skin and in proliferating
B cells of the tonsil [1]. Similarly to IL-1α, IL-1β, IL-1Ra, IL-18, IL-
33, IL-36, and IL-37, IL-38 lacks a signal peptide. The natural N
terminus of IL-38 is still unknown, and there is no caspase-1r B.V. This is an open access article
ine, Division of Respirology,
ool of Medicine, Kurume 830-
Hoshino).consensus cleavage site [2]. A recent study has demonstrated that
IL-38 inhibited Candida albicans-induced IL-17, as well as IL-22
production from peripheral blood mononuclear cells (PBMC). In
contrast, LPS-induced IL-6 production was signiﬁcantly higher in
the presence of IL-38 [3]. The precise biological roles of IL-38 are
still unknown.2. Materials and methods
2.1. Recombinant human IL-38 protein
The full-length human IL-38 cDNA [1] with a His tag at the
C-terminal, converted to an Escherichia coli-type codon, was syn-
thesized in accordance with the GenBank sequence (BC103968.1).
The synthesized human IL-38 cDNA was subcloned into the
pET28a (þ) expression vector (Novagen, Tokyo, Japan). E. coli
(BL21DE3) was transformed with pET28a/human IL-38. Re-
combinant human IL-38 was isolated as reported previously [4].
The full-length human IL-38 cDNA with a His tag at the C-terminal
was subcloned into the pPSC8 expression vector (Protein Sciences
Corporation, Meriden, CT, USA), and designated as pPSC8/human
IL-38. We also isolated recombinant human IL-38 protein from SF9under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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38.2.2. Human IL-38 cDNA-transfected cells
The synthesized human IL-38 cDNA was subcloned into the
pEF1α-IRES vector (Clontech Laboratories, Inc., Mountain View,
CA, USA). The pEF1α-IRES/human IL-38 plasmid was transfected
into 293T cells (human embryonic kidney cell line) using FuGENEs
6 DNA transfection regent (Promega KK, Tokyo, Japan). The pEF1α-
IRES/human IL-38 plasmid was also transfected into the murine
myeloma cell line P815 using a Gene Pulser II (Bio-Rad, Hercules,
CA), as reported previously [5].
2.3. Establishment of an anti-human IL-38 polyclonal antibody and
monoclonal antibody
Speciﬁc pathogen-free (Japanese White) rabbits were im-
munized with recombinant human IL-38 protein, and antisera
were obtained. Puriﬁed rabbit anti-human IL-38 polyclonal anti-
body was generated from the antisera in our laboratory, as re-
ported previously [5,6]. An anti-human IL-38 monoclonal antibody
(mAb) was established by fusion of the mouse myeloma cell line
X-63・Ag8/653 with spleen cells isolated from a BALB/c mouse
immunized with the recombinant human IL-38 protein, as re-
ported previously [5,6]. We generated ascites using this cell line,
and puriﬁed the antibody using a protein G column. The puriﬁed
mAb was labeled with FITC, as reported previously [7].
2.4. Establishment of a human IL-38 sandwich enzyme-linked im-
munosorbent assay system
A human IL-38 sandwich enzyme-linked immunosorbent assay
(ELISA) system was established, as reported previously. Brieﬂy, a
mouse anti-human IL-38 primary mAb (clone H160A) dissolved at
2 μg/mL in phosphate-buffered saline (PBS) was dispensed into
enzyme-linked immunosorbent assay (ELISA) plates in aliquots of
100 μL/well and left undisturbed overnight at 4 °C to allow it to
become immobilized. The plates were then washed three times
with 200 μL of Quantikine Wash Buffer 1 (R&D Systems, Minnea-
polis, MN, USA), and 200 μL/well of 10% Block Ace blocking solu-
tion (Nakarai Tesque, Kyoto, Japan) was added and left for at least
one hour at room temperature to prevent nonspeciﬁc adhesion of
the secondary antibody to the plates. The plates were then washed
three times. Human serum samples were then aliquoted at 100 μL/
well. Recombinant human IL-38 protein diluted to 600, 300, 150,
75, 37.5, 18.75 and 9.375 ng/mL was used as the standard. After 2 h
of incubation at room temperature, each well was washed three
times. Next, 1 μg/mL biotin-labeled mouse anti-human IL-38 sec-
ondary mAb (clone H127C) was dispensed at 100 μL/well, followed
by incubation for 90 min at room temperature, and then each well
was washed four times. This was followed by addition of 100 μL of
0.5 μg/mL streptavidin-bound horseradish peroxidase (Millipore,
Tokyo, Japan) to each well, and the plates were left undisturbed for
30 min at room temperature. Each well was then washed three
times. A color development substrate solution (ELISA POD Sub-
strate TMB kit; Nakarai Tesque) was then added at 100 μl/well, and
the plates were left undisturbed for 30 min at room temperature,
followed by addition of a stop solution (1 M sulfuric acid; Wako,
Tokyo, Japan) at 100 μL/well to stop the enzyme reaction. The
amounts of the human IL-38 protein were determined by mea-
suring the absorbance at 450 nm. The limit of sensitivity of this
ELISA system was o9.35 ng/mL.2.5. Protease reaction and Western blotting analysis
Digestion of recombinant human IL-38 and pro-IL-1β protein
(Sino Biological Inc., Beijing, China) by recombinant caspase 1,
chymase, and PR3 (Sigma, St. Louis, MO, USA) was performed as
reported previously [8,9]. Then, we performed Western blotting
analysis to evaluate the reactions by using a rabbit anti-human IL-
38 polyclonal antibody (established in our laboratory) and rabbit
anti-human pro-IL-1β (Santa Cruz Biotechnology, Dallas, TX, USA).
2.6. Human subjects
Synovial tissue was obtained from knee joints of patients with
rheumatoid arthritis (RA) (n¼7) and osteoarthritis (OA) (n¼2),
who underwent knee surgery at the Nagata Orthopedic Hospital
(Omuta, Japan). All samples were ﬁxed in formalin and embedded
in parafﬁn. Serum samples were obtained from 137 RA patients
(22 males and 115 females) and 26 OA patients (5 males and 21
females), who had been consecutively monitored at the Kurume
University Hospital or the Kurume University Medical Center
(Kurume, Japan) from 2005 to 2010. Serum samples were also
obtained from 56 age-matched healthy volunteers (33 males and
23 females). Sample collection and all procedures were approved
by the ethics committee of Kurume University in accordance with
the ethical standards of the Helsinki Declaration of 1975. Informed
consent was obtained from all patients and healthy volunteers.
2.7. Histological examinations and immunohistochemical staining
Immunohistochemical staining was performed as reported
previously [5,6,10]. Brieﬂy, synovial tissues were ﬁxed with 10%
formalin and embedded in parafﬁn wax. Serial sections (4 μm
thick) were cut from parafﬁn-embedded tissues, placed on poly-L-
lysine-coated slides, and then incubated overnight at 55–60 °C.
Deparafﬁnized sections were autoclaved for 3–4 min in 10 mM
citric acid buffer (pH 6.0). Deparafﬁnized sections were im-
munostained with anti-human IL-38 mAb (clone H127C [mouse
IgG2b], 0.5 μg/mL) for 60–90 min at room temperature. Positive
reactivity was identiﬁed using biotin-labeled goat anti-mouse and
rabbit IgG, peroxidase-streptavidin and 3-3′-diaminobenzidine-
4HCl (Dako, Kyoto, Japan). Anti-human IL-38 clone H127C was also
used for intracellular staining for ﬂow cytometry (data not shown).
2.8. IL-38-deﬁcient mice
IL-38-deﬁcient mice (Il1f10tm1Lex/Mmucd), backcrossed
9 times with C57BL/6NCrl (B6) mice, were obtained from the
Mutant Mouse Regional Resource Center, University of California
Davis (West Sacramento, CA). Age-matched female B6 wild-type
(WT) mice, purchased from Charles River Japan (Yokohama, Ja-
pan), were used as controls. All procedures were approved by the
Committee on the Ethics of Animal Experiments, Kurume Uni-
versity (Approval no. 2013-243). Animal care was provided in ac-
cordance with the procedures outlined in the “Principles of la-
boratory animal care” (National Institutes of Health Publication
no.86-23, revised 1985). All efforts were made to minimize the
suffering of animals used in this study.
2.9. Experimental RA mouse model
Pro-arthritic serum was isolated from K/BxN mice as described
previously [11,12]. K/BxN arthritis was induced by intraperitoneal
injection of 150 μL K/BxN serum on day 0 of each experiment.
Arthritis was graded using a 0–16 clinical scale (0–4) per paw, as
described previously [13]. Histological assessment was performed
on parafﬁn-embedded 4-μm sections stained with hematoxylin
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graded in a blinded manner emplying a 0–5 scale, in accordance
with an established system [14].
2.10. Real-time quantitative RT-PCR
Total RNA was isolated from mouse ankle joints using the
RNeasy minikit (Qiagen, Tokyo, Japan). Total RNA was extracted
from mouse ankle joints as described previously [15,16]. Brieﬂy,
the skin around the ankle joints was removed, and tissue from the
distal tibia to the mid paw was carefully collected to avoid con-
tamination with bone marrow. The harvested ankles were im-
mersed in RNAlater (Qiagen) to minimize degradation of RNA. The
samples were treated with proteinase K (55 °C, 30 min), and cells
were disrupted with Buffer RLT lysis buffer (Qiagen). For the fol-
low-up real-time-quantitative PCR (qPCR) assays, puriﬁed RNA
was converted in each instance into cDNA using a Quantitect re-
verse transcription kit (Qiagen). qPCRs were performed with SYBR
Green Mastermix (Qiagen) using primers for mouse and human β-
actin and IL-38 and mouse IL-1β and IL-6 (Qiagen) on an Mx3000p
PCR machine (Stratagene, La Jolla, CA). Relative expression was
calculated using the comparative threshold cycle method, as re-
ported previously [17].
2.11. Statistical analysis
Results were expressed as means7standard error of the mean
(SEM). P values were calculated by Mann–Whitney U-test. Differ-
ences were considered signiﬁcant at Po0.05.Fig. 1. Characteristics of human IL-38. (A) Western blotting analysis using anti-human IL
approximately 18 kDa IL-38 protein in the cells and supernatants. Line 1: Cell lysate of
transfected 293T cells. Line 3: Supernatant of vector-transfected 293T cells. Line 4: Sup
combinant human IL-38 (rhIL-38) protein with His tag at C-terminal was used. (B) Standa
H160A). (C) Caspase-1, chymase, and PR3 can cleave recombinant human pro-IL-1β (hp
rabbit anti-human pro-IL-1β polyclonal Ab (Santa Cruz Biotechnology, Dallas, TX) and r3. Results
3.1. Characteristics of human IL-38
Western blotting analysis showed that human IL-38 cDNA-
transfected 293T cells expressed IL-38 protein of approximately
18 kDa in the cells and in the supernatant (lanes 2 and 4 in Fig1A).
The molecular mass of recombinant human IL-38 protein fused
with a His tag was approximately 20 kDa (Fig. 1A). We established
anti-human IL-38 mAbs as reported previously [5,6]. In this study,
we newly established a human IL-38 ELISA system using two anti-
human IL-38 mAbs (clone H160A [mouse IgG1], clone H127C
[mouse IgG2b]) (Fig. 1B). Sandwich ELISA analysis revealed that
the level of IL-38 in the supernatants of human IL-38 cDNA-
transfected 293T cells was 39.0 ng/mL. In contrast, IL-38 protein
was not detectable in 293T cells transfected with the vector only.
Taken together, the data indicated that human IL-38 protein is
soluble, despite the fact that the IL-38 gene does not have a signal
peptide. It has been reported that, like other IL-1 family cytokines,
IL-18 can be cleaved by caspase-1, chymase, and PR3 [18]. There-
fore we examined whether caspase-1, chymase, and PR3 can
cleave recombinant human IL-38 protein. As shown in Fig. 1C, all
three enzymes cleaved recombinant human IL-1β, but not human
IL-38.
3.2. IL-38 expression in RA serum and synovium
We examined the serum levels of IL-38 in RA patients, OA pa-
tients and healthy donors by using ELISA for human IL-38, and the
corresponding levels were 5.770.94 ng/mL (n¼137),-38 mAb (H127C) showed that human IL-38 cDNA-transfected 293T cells expressed
vector-transfected 293T cells. Line 2: Cell lysate of human IL-38 cDNA-transfected-
ernatant of human IL-38 cDNA-transfected-transfected 293T cells. As control, re-
rd curve of human IL-38 sandwich ELISA using anti-human IL-38 mAbs (H127C and
ro-IL-1β), but not rhIL-38 protein. Western blotting analysis was performed using
abbit anti-human IL-38 polyclonal Ab (established at our laboratory).
Fig. 2. IL-38 expression in RA serum and synovium. (A) Serum levels of IL-38 in RA, OA patients and healthy donors. Serum levels of IL-38 was examined by IL-38 ELISA.
Twenty-one of 137 RA (15.3%), one of 26 OA patients (3.9%) and 5 of 56 controls (8.9%) were elevated above the detection limit. Detection limit is 9.35 ng/ml. (B) IL-38 is
expressed in RA, but not OA synovium. Synovial tissues were obtained from 7 RA patients and 2 OA patients. Synovial tissues were immunostained with anti-human IL-38
mAb [H127C, mouse IgG2b] (b, c, d) or isotype-matched control mouse IgG2b Ab (a). Representative sections of synovial tissues from 2 RA patients (b, c) and a patient with
OA (d) are shown. Original magniﬁcation: 200.
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tively. Twenty-one of 137 RA (15.3%) patients, one of 26 OA pa-
tients (3.9%), and 5 of 56 controls (8.9%) showed elevated IL-38
levels above the limit of detection (9.35 ng/mL) of our ELISA assay.Fig. 3. IL-38 gene deﬁciency enhances joint inﬂammation in RA mouse model. Arthritis
administration of K/BxN mouse serum. (A) IL-38 mRNA in ankle joints (8 ankles/group fr
transfer. *po0.05, normal vs. inﬂamed joints. (B) Clinical score of K/BxN serum transfer a
WT vs. IL-38/ mice. Data are representative of at least 2 separate experiments. (C
independent experiments (10 ankles/group from two separate experiments). *po0.0
presentative WT (left) and IL-38/ mice (right). Hematoxylin and eosin stained; origina
two separate experiments) was examined at day 7 or 8 arthritis. *po0.05, WT vs. IL-38However, there were no signiﬁcant differences in serum IL-38 le-
vels among RA patients, OA patients and healthy donors (Fig. 2A).
Next, we evaluated IL-38 expression in the synovial tissue of RA
and OA patients. Synovial tissue samples from 7 RA patients andwas initiated in female IL-38/ mice and control B6 WT mice via intraperitoneal
om two separate experiments) was determined before or 8 days after K/BxN serum
rthritis in WT and IL-38/ mice on a 0–16 scale (n¼5/group), *po0.05, **po0.01,
) Histomorphometric quantiﬁcation of arthritic tissue. Data were pooled in two
5, WT vs. IL-38/ mice. (D) Histopathologic ﬁndings in the ankle joints of re-
l magniﬁcation 40. (E) Cytokine mRNA in the ankle joints (10 ankles/group from
/ mice. Values in A–C and E are the mean7SEM.
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We found that IL-38 protein was highly expressed in the synovial
lining of RA synovium (b, c in Fig. 2B), whereas no im-
munohistochemical reaction was detected in RA synovium using
control mouse IgG2b Ab (a in Fig. 2B). Moreover, IL-38 protein was
expressed very weakly in the OA synovium lining (Fig. 2B, d). No
immunohistochemical reaction was detected in OA synovium
using control Ab (data not shown).
3.3. IL-38 gene deﬁciency exacerbates disease severity in autoanti-
body-induced arthritis
The prominent expression of IL-38 protein in synovium of RA
patients was conﬁrmed. However, its expression in mouse joints
had not been investigated. K/BxN arthritis is an IgG autoantibody-
mediated immune complex mouse arthritis that results in marked
joint tissue inﬂammation within a few days after intraperitoneal
injection of arthritogenic serum [11]. IL-38 mRNA was signiﬁcantly
increased in mouse joints during autoantibody-induced arthritis
(Fig. 3A). To explore the role of IL-38 in a RA mouse model, we
induced K/BxN serum transfer arthritis in female B6 mice lacking
the IL-38 gene (IL-38 /). IL-38 deﬁcient mice (Il1f10tm1Lex/
Mmucd) used in this study, were backcrossed 9 times with C57BL/
6NCrl (B6) mice. We did not observe a signiﬁcant phenotype in
C57/BL6 background IL-38 deﬁcient mice until 18 weeks after
birth. As controls, we used age- and sex-matched B6 WT mice. We
found that IL-38/ mice exhibited signiﬁcant exacerbation of the
clinical scores during arthritis, when compared with control WT
B6 mice (Fig. 3B). Histological analysis was performed as shown in
Fig. 3C. Histomorphometric quantiﬁcation of the arthritic changes
in the joint tissues conﬁrmed the clinical assessment, with sig-
niﬁcant increases in inﬂammation and bone erosion scores in
IL-38/ mice (Fig. 3D). The corresponding expression of mRNA
for IL-1β and IL-6 was signiﬁcantly more up-regulated in the ankle
joints obtained from IL-38/ mice as compared with control
mice (Fig. 3E).4. Discussion
IL-38 lacks a signal peptide and has no caspase-1 consensus
cleavage site [2]. Our in vitro study showed that human IL-38
protein was not cleaved by recombinant caspase-1, chymase, or
PR3 in vitro. However, overexpression of human IL-38 cDNA pro-
duced a soluble form of IL-38, as reported previously [1]. We also
found that human IL-38 protein was detectable at higher levels in
sera of RA patients as well as at lower concentrations in OA pa-
tients and normal subjects. Consistent with previous ﬁndings [1],
our present results show that human IL-38 protein is produced as
a soluble form and may function as a secreted ligand. However, we
did not examine the natural N terminus of the soluble IL-38, and
further analysis will therefore be needed.
Clinical studies using anti-inﬂammatory cytokine monoclonal
antibodies such as anti-TNF-α and anti-IL-6 have revealed that
inﬂammatory cytokines are involved in the development of RA.
Moreover, previous studies have shown that recombinant IL-1Ra
(anakinra) can be used for treatment of systemic juvenile idio-
pathic arthritis and a proportion of RA patients [3]. It has been
suggested that IL-38 may have an antagonistic role, because of its
amino acid homology to naturally occurring IL-1Ra [2]. Recently, a
study using an immobilized extracellular IL-36R domain-Fc con-
struct in a low-sensitivity binding assay has suggested that IL-38
binds to the extracellular domain of recombinant IL-1Rrp2 (IL-
36R), and this ﬁnding will need to be conﬁrmed [3]. In the present
study, we showed that synovial tissues obtained from RA patients,
but not OA patients, strongly expressed IL-38 protein and that theserum IL-38 levels in RA patients were higher (but not sig-
niﬁcantly) than those in control subjects. Moreover, disease se-
verity and expression of the IL-1β and IL-6 genes in the IL-38 /
RA model mice were more marked than those in WT mice, sug-
gesting that IL-38 acts as an anti-inﬂammatory cytokine in our
mouse RA model.
Although IL-38 protein has been demonstrated to be expressed
in human skin and tonsil [1], we report here that IL-38 protein is
also strongly expressed in synovia of RA patients. Synovial tissue-
derived IL-38 may play a local role in the development of joint
inﬂammation. In the present study, the soluble form of IL-38
protein was detected in the sera obtained from 15.3% and 3.9% of
RA and OA patients, respectively. However, serum levels of IL-38 in
RA patients did not correlate with their disease activity, disease
duration, or treatment (data not shown). Soluble IL-38 in the
serum could be a speciﬁc RA diagnostic marker in a subset of
patients. In other autoimmune diseases, 7 of 37 SLE (18.9%) and
none of 5 adult onset Still's disease patients were elevated above
the limit of detection (manuscript in preparation). Further analysis
of the role of IL-38 in human autoimmune disease is needed and
will require an analysis of larger patient populations.
A study using an antibody-induced arthritis model has shown
that IL-1β is required for disease progression [19]. Furthermore, IL-
1Ra-deﬁcient mice on a BALB/c background spontaneously de-
velop chronic inﬂammatory arthropathy [20]. The pathogenic role
of the IL-1 pathway has been conﬁrmed in an experimental mur-
ine arthritis model. In our model, IL-38 expression was up-regu-
lated, at least at the mRNA level, during arthritis, suggesting that it
may participate in the development of arthritis. B6 background
IL-38 / mice developed more severe arthritis than control WT
mice, associated with enhanced expression of IL-1β and IL-6 in the
ankle joints. It has been shown that IL-1Ra and IL-38 inhibit C.
albicans-induced Th17 production, as well as IL-22 production by
PBMC [3]. Like IL-1Ra, IL-38 may have an antagonistic role, in view
of its amino acid homology with naturally occurring IL-1Ra [1,3].
Therefore, IL-38 may attenuate joint inﬂammation by inhibiting IL-
1-induced inﬂammation. Systemic administration of recombinant
mouse IL-38 (1 μg/mouse) did not inhibit arthritis development in
the K/BxN arthritis model (data not shown). However, the precise
dosage of recombinant IL-38 and the drug administration route
required to inhibit arthritis development needs to be conﬁrmed. It
is well known that IL-1 family members IL-1β and IL-18 have both
inﬂammatory and anti-inﬂammatory effects in vivo [18,,21].
Especially important, these cytokines have inﬂammatory and anti-
inﬂammatory effects depending on dose. Whereas IL-38 gene
deﬁciency enhanced arthritis, systemic administration of re-
combinant IL-38 protein did not inhibit arthritis development.
Therefore, it is possible that IL-38 may have dose dependent ef-
fects in inﬂammatory vs. anti-inﬂammatory responses. Further
analysis is required to test this hypothesis.
In summary, IL-38 exerts anti-inﬂammatory effects in a RA
mouse model, and is structurally and functionally related to re-
ceptor antagonists, including IL-1Ra.Conﬂict of interest
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